Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. (CYT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cyt · stock forecast · 5 analysts (3M) · FMP · updated Jun 28, 2024
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$2.00
Consensus
$2.00
-33.6% upside
Low
$2.00
Median: $2 · Last Close: $3.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CYT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-01-05 | B of A Securities | Downgrade ↓ | Neutral→Underperform |
| 2023-05-12 | Wedbush | Maintains | Outperform→Outperform |
| 2023-05-11 | Wedbush | Maintains | Outperform→Outperform |
| 2023-02-03 | Morgan Stanley | Downgrade ↓ | Equal Weight→Underweight |
| 2023-02-02 | Morgan Stanley | Downgrade ↓ | Equal Weight→Underweight |
| 2023-01-30 | B of A Securities | Downgrade ↓ | Buy→Neutral |
| 2023-01-29 | B of A Securities | Downgrade ↓ | Buy→Neutral |
| 2023-01-20 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2023-01-19 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2022-09-09 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
Wall Street analysts have recently issued updated ratings on Cyteir Therapeutics, Inc. (CYT) stock. Of the recent 18 rating actions, 0 were upgrades and 9 were downgrades. 5 analysts currently cover CYT.
Analyst Recommendation Trends
CYT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-1.15
EPS Next Year
$-1.36
↑ 18.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast CYT EPS of $-1.15 for the current fiscal year, based on estimates from 1 analysts. The CYT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CYT stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CYT price target is $2.00 (-33.6% upside), with an analyst consensus of Buy.
Cyteir Therapeutics, Inc. trades on NASDAQ under the ticker CYT. The CYT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 40% of covering analysts.
Frequently asked questions
CYT forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month CYT price target is $2.00, with a high forecast of $2.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies -33.6% potential upside from the current price of $3.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.